Roche Specialty Market Focus Provides Refuge In “Unstable Environment”
Executive Summary
Roche's return to prominence in the primary care market will wait until at least 2006, the company indicated during a July 24 analyst meeting in Zurich
You may also be interested in...
Roche Vision Of Rx Future Includes IT And China, But Not Large Sales Force
Roche is keeping a close watch on information technology companies as potential emerging competitors for the pharmaceutical industry, CFO Erich Hunziker told the recent J.P. Morgan health care conference in San Francisco
Roche Vision Of Rx Future Includes IT And China, But Not Large Sales Force
Roche is keeping a close watch on information technology companies as potential emerging competitors for the pharmaceutical industry, CFO Erich Hunziker told the recent J.P. Morgan health care conference in San Francisco
Xenical OTC Switch Plans Underway; GSK Pays $100 Mil. For Rights
Roche and GlaxoSmithKline appear to be moving quickly on an Rx-to-OTC switch application for the anti-obesity agent Xenical (orlistat)